NCT00353678View on ClinicalTrials.gov

Factor Xa Inhibitor YM150 for the Prevention of Blood Clot Formation in Veins After Scheduled Hip Replacement (ONYX-2)

PHASE2CompletedINTERVENTIONAL
Enrollment

1,141

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

August 31, 2007

Study Completion Date

August 31, 2007

Conditions
Thromboembolism
Interventions
DRUG

YM150

Trial Locations (79)

1090

Vienna

1130

Vienna

2300

Copenhagen

2409

Elverum

2500

Tynset

2730

Herlev

2970

Hørsholm

4201

Valmiera

6020

Innsbruck

7006

Trondheim

8600

Silkeborg

10003

Cáceres

11000

Belgrade

11883

Stockholm

12004

Castellon

12157

Berlin

16766

Kremmen OT Somerfeld

17027

Pietra Ligure

18000

Prague

Niš

20089

Rozzano

20097

S. Donato Milanese

20123

Milan

20162

Milan

21000

Novi Sad

24000

Subotica

27100

Pavia

27259

Kladno

28006

Madrid

28035

Madrid

28040

Madrid

28046

Madrid

33100

Udine

34000

Kragujevac

39120

Cantoria

39185

Kalmar

40136

Bologna

40620

Jyväskylä

41685

Gothenburg

42100

Reggio Emilia

43100

Parma

46010

Valencia

52185

Falköping

59185

Motala

60528

Frankfurt am Main

66250

Brno

67401

Třebíč

71000

Sarajevo

71706

Markgröningen

73300

Foča

75000

Tuzla

90220

Oulu

92421

Schwandorf in Bayern

111539

Moscow

117869

Moscow

119049

Moscow

129327

Moscow

194291

Saint Petersburg

195067

Saint Petersburg

400040

Volgograd

443095

Samara

454026

Chelyabinsk

460000

Orenburg

603155

Nizhny Novgorod

06112

Halle

166 73

Athens

151 27

Melíssia

LV 1004

Riga

LV 1005

Riga

LT-50009

Kaunas

LT-04130

Vilnius

15-276

Bialystok

40-635

Katowice

31-826

Krakow

20-718

Lublin

20-951

Lublin

00-909

Warsaw

974 01

Banska Bysterica

034 26

Ružomberok

Sponsors
All Listed Sponsors
collaborator

Astellas Pharma Europe B.V.

INDUSTRY

lead

Astellas Pharma Inc

INDUSTRY